Ethypharm tightens pricing on buyout debt
Ethypharm, the French pharmaceutical firm, has allocated a €337m seven year term loan ‘B’ at tighter pricing than initial guidance, following a heavy oversubscription.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts